NLRP3 Inflammasome: Key Role in the Pathophysiology of Cardiac Disorders and its Potential as a Therapeutic Target

Navneet Arora, Ranjeet Kumar
{"title":"NLRP3 Inflammasome: Key Role in the Pathophysiology of Cardiac Disorders and its Potential as a Therapeutic Target","authors":"Navneet Arora, Ranjeet Kumar","doi":"10.2174/012210299x256054231020060356","DOIUrl":null,"url":null,"abstract":"Abstract: The NLRP3 inflammasome holds a pivotal position in the pathophysiological landscape of cardiac disorders, presenting itself as a promising therapeutic target. Central to this role are the proinflammatory cytokines Interleukin (IL)-1 and IL-18, which emerge as major players orchestrated by the activation of the NLRP3 inflammasome. This activation culminates in pyroptosis, a programmed form of cell death. While controlled activation of NLRP3 supports tissue repair, its excessive activation yields adverse consequences. Within the spectrum of cardiovascular diseases, ranging from abdominal aortic aneurysm to calcific aortic valve disease, the NLRP3 inflammasome is notably implicated. Atherosclerosis, myocardial infarction, diabetic cardiomyopathy, heart failure, and dilated cardiomyopathy collectively contribute to the genesis of inflammatory conditions. Key to this process is the nucleotide oligomerization domain-containing leucine-rich repeat protein 3 (NLRP3) inflammation, necessitating both priming and activation signals to orchestrate inflammation. Extensive scientific evidence substantiates the critical role of the NLRP3 inflammasome in cardiac disorders. Experimental models and clinical studies converge, highlighting its contribution to the intricate web of inflammatory pathways that underlie cardiac pathologies. This deeper understanding has spurred interest in targeting the NLRP3 inflammasome as a therapeutic avenue. Efforts to modulate the NLRP3 inflammasome are underway, aiming to temper its hyperactivity without disrupting its beneficial functions. Strategies involve small molecule inhibitors and biological agents, targeting various points along the signaling cascade. By selectively intervening in the NLRP3 pathway, researchers aspire to mitigate inflammatory responses, potentially ameliorating the progression of cardiac disorders. In conclusion, the NLRP3 inflammasome is a central orchestrator in the pathophysiology of diverse cardiac disorders. Its dual nature, capable of both driving repair and provoking harm, accentuates its significance as a therapeutic target. Scientific endeavors are actively unraveling its complexities, fostering the development of innovative interventions that could potentially revolutionize the management of cardiac inflammatory conditions.","PeriodicalId":479738,"journal":{"name":"Current Indian Science","volume":"73 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Indian Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/012210299x256054231020060356","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: The NLRP3 inflammasome holds a pivotal position in the pathophysiological landscape of cardiac disorders, presenting itself as a promising therapeutic target. Central to this role are the proinflammatory cytokines Interleukin (IL)-1 and IL-18, which emerge as major players orchestrated by the activation of the NLRP3 inflammasome. This activation culminates in pyroptosis, a programmed form of cell death. While controlled activation of NLRP3 supports tissue repair, its excessive activation yields adverse consequences. Within the spectrum of cardiovascular diseases, ranging from abdominal aortic aneurysm to calcific aortic valve disease, the NLRP3 inflammasome is notably implicated. Atherosclerosis, myocardial infarction, diabetic cardiomyopathy, heart failure, and dilated cardiomyopathy collectively contribute to the genesis of inflammatory conditions. Key to this process is the nucleotide oligomerization domain-containing leucine-rich repeat protein 3 (NLRP3) inflammation, necessitating both priming and activation signals to orchestrate inflammation. Extensive scientific evidence substantiates the critical role of the NLRP3 inflammasome in cardiac disorders. Experimental models and clinical studies converge, highlighting its contribution to the intricate web of inflammatory pathways that underlie cardiac pathologies. This deeper understanding has spurred interest in targeting the NLRP3 inflammasome as a therapeutic avenue. Efforts to modulate the NLRP3 inflammasome are underway, aiming to temper its hyperactivity without disrupting its beneficial functions. Strategies involve small molecule inhibitors and biological agents, targeting various points along the signaling cascade. By selectively intervening in the NLRP3 pathway, researchers aspire to mitigate inflammatory responses, potentially ameliorating the progression of cardiac disorders. In conclusion, the NLRP3 inflammasome is a central orchestrator in the pathophysiology of diverse cardiac disorders. Its dual nature, capable of both driving repair and provoking harm, accentuates its significance as a therapeutic target. Scientific endeavors are actively unraveling its complexities, fostering the development of innovative interventions that could potentially revolutionize the management of cardiac inflammatory conditions.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
NLRP3炎性小体:在心脏疾病病理生理中的关键作用及其作为治疗靶点的潜力
摘要:NLRP3炎性小体在心脏疾病的病理生理中占有举足轻重的地位,是一个有前景的治疗靶点。这一作用的核心是促炎细胞因子白介素(IL)-1和IL-18,它们在NLRP3炎性小体的激活中扮演着重要角色。这种激活最终导致焦亡,这是一种程序化的细胞死亡形式。虽然NLRP3的可控激活支持组织修复,但其过度激活会产生不良后果。在一系列心血管疾病中,从腹主动脉瘤到钙化主动脉瓣疾病,NLRP3炎性体都与之密切相关。动脉粥样硬化、心肌梗死、糖尿病性心肌病、心力衰竭和扩张型心肌病共同促成炎症条件的发生。这个过程的关键是核苷酸寡聚化结构域的富含亮氨酸重复蛋白3 (NLRP3)炎症,需要启动和激活信号来协调炎症。广泛的科学证据证实了NLRP3炎性体在心脏疾病中的关键作用。实验模型和临床研究的融合,突出了其对心脏病理基础的复杂炎症通路网络的贡献。这种更深层次的理解激发了人们对靶向NLRP3炎性体作为治疗途径的兴趣。调节NLRP3炎性体的努力正在进行中,目的是在不破坏其有益功能的情况下缓和其过度活跃。策略包括小分子抑制剂和生物制剂,针对信号级联的各个点。通过选择性干预NLRP3通路,研究人员希望减轻炎症反应,潜在地改善心脏疾病的进展。综上所述,NLRP3炎症小体在各种心脏疾病的病理生理中起着中心协调作用。它的双重性质,既能促进修复又能引发伤害,这凸显了它作为治疗靶点的重要性。科学努力正在积极地揭示其复杂性,促进创新干预措施的发展,这可能会彻底改变心脏炎症状况的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Medicinal Value of Mushroom: A Deeper Insight FDA Approval of Zituvio for Type 2 Diabetes Superhydrophobic Stainless Steel Mesh through Chemical Vapour Deposition of TMCS for Effective Oil-Water Separation What are Proteome Atlases good for? Recent Advances in Heterogeneously Catalyzed Acceptorless Dehydrogenation of Alcohols to Carbonyl Derivatives and N-heterocyclic Compounds
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1